News

Key FDA approvals, clinical trial insights, and expert commentary in allergy care from the first half of 2025.

The Q2 recap for nephrology spotlights key FDA decisions and top coverage from the 62nd European Renal Association Congress.

Our recap of Q2 2025 in cardiology spotlights 3 FDA headlines, trial news, and new episodes of Don't Miss a Beat.

Q2 2025 saw new therapies approved for rare rheumatological conditions and exciting research out of EULAR.

According to recent research, more patients surviving heart diseases correlates directly to higher mortality rates for ischemic and chronic heart conditions.

Explore key advancements in endocrinology from Q2 2025, including FDA approvals and groundbreaking diabetes research shaping future treatments.

Sidbury highlights updates to previous guidelines on the management of atopic dermatitis using approved topical and systemic therapies.

This Q2 psychiatry recaps promising data of COMP360 for treatment-resistant depression, the expansion of clozapine access, and experts weighing in on new data and ethical debates.

June 2025 highlights groundbreaking advancements in endocrinology, featuring key insights from major conferences on diabetes, heart health, and kidney care.

Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in hematology.

Q2 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

Q2 2025 allergy news highlights include FDA actions on HAE therapies, warnings for antihistamines, and new sinus surgery guidelines for chronic rhinosinusitis.

A review of the 16 novel drugs approved by the US Food and Drug Administration during the first half of 2025, with links to coverage from MJH Life Sciences publications.

Our June 2025 recap highlights significant advancements in cardiology, including new drug approvals and pivotal trial results.

Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in eyecare.

The results of the ZENITH trial have encouraged the expansion of sotatercept’s label to patients with prior background therapy.

Breakthroughs in narcolepsy, idiopathic hypersomnia, OSA, and RLS signal a shift toward personalized care and novel therapies. Check out this June 2025 sleep month in review.

The month in review spotlights renal regulatory news and clinical trial data as well as coverage of the 62nd European Renal Association Congress.

A relatively quiet quarter for hematology, punctuated by both successes and failures in clinical trials and a handful of Orphan Drug and Fast Track designations.

This month in review captures 5 allergy news in June, from FDA approvals to phase 3 data.

The month in review spotlights hepatic regulatory news, new clinical trial data, and novel research about liver disease risk factors.

Our Q2 2025 recap for ophthalmology highlights 5 regulatory updates, 5 important trial announcements, and top perspectives in eyecare.

June 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

This FDA news recap highlights some of the most notable approvals and actions by the organization in dermatology during Q2 2025.

The month in review spotlights perspectives on collaborative GI care, updates in C diff, and new research about disorders of gut brain interaction.

The FDA distributed several designations and many trials successfully met their endpoints during an eventful June for hematology.

Discover groundbreaking FDA approvals in 2025 that redefine treatment standards, enhance patient care, and address critical public health needs.

In our recap for Q2 in dermatology, we spotlight clinical trial findings, recent updates, and advancements in different disease states.